Cardinal Health’s (CAH) Presource kit plastic syringe makers Jiangsu Shenli Medical Production Co. Ltd and Jiangsu Caina have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with FDA regulations.Following the recent warning, the import alert was expanded to preventJiangsu Shenli’s enteral syringes from entering the United States. The ...

DUBLIN, Ohio, July 23, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be av ...

Cardinal Health (CAH) ended the recent trading session at $95.97, demonstrating a +0.59% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.39%. Elsewhere, the Dow saw an upswing of 0.6%, while the tech-heavy Nasdaq depreciated by 2.77%.Heading into today, shares of the prescription drug distributor had lost 8.34% over the past month, lagging the Medical sector's gain of 1.98% and the S&P 500's gain of 4.43% in that time.Market participants will ...

In the latest market close, Cardinal Health (CAH) reached $93.74, with a -0.38% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.53%, while the tech-heavy Nasdaq appreciated by 0.4%.The prescription drug distributor's shares have seen a decrease of 6.09% over the last month, not keeping up with the Medical sector's gain of 0.79% and the S&P 500's gain of 3.78%.Market participants will be closely following the ...

The latest trading session saw Cardinal Health (CAH) ending at $96.01, denoting a -0.9% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.07%. Elsewhere, the Dow saw a downswing of 0.13%, while the tech-heavy Nasdaq appreciated by 0.14%.Shares of the prescription drug distributor witnessed a loss of 1.98% over the previous month, beating the performance of the Medical sector with its loss of 1.99% and underperforming the S&P 500's gain of 4.34%.Analysts ...

PDUFA Target Action Dates in Late December 2024Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 YearsSAN DIEGO, July 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont wo ...

Richard Drury Welcome back to another edition of upcoming dividend increases. We are starting July's increases. If you are trading, be aware of the modified market hours next week. The market will close at 1 p.m. EST on the 3rd and be closed on July 4th. We also have dividend king Sysco Corporation extending its 54-year streak with a 2% increase. The overall group of companies has an average increase of 4.1% and a median of 3.7%. My investment strategy involves buying, holding, and adding to companies t ...

100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of 17-OHP on Atumelnant (80 mg), Beginning at Two Weeks and Sustained Through 12 Weeks In the ADCS Trial, Atumelnant (80 mg) Normalized 24-hr Urinary Free Cortisol Levels for 100% of Participants (n=5) During Treatment Management to Host Investor Conference Call Today at 4:30 PM ET and Onsite ...

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In addition, ...

-          CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control     -          30% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose at Week 28 while Maintaining Androgen Control versus 0% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Supraphysiologic Glucocorticoid Dosing and Androgen Excess  ...